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Prothymosin  a (PTA) is a small highly acidic nuclear protein
related to normal cell proliferation (Haritos et al, 1984;
Eschenfeldt and Berger, 1986; Goodall et al, 1986; Gomez et al,
1989; Conteas et al, 1990; Zalvide et al, 1992). Immuno-
histochemical studies have shown that PTA is expressed in pro-
liferating but not in quiescent cells in all tissues studied so far
(Conteas et al, 1990; Fraga et al, 1993; Gallego et al, 1992; Garcia
et al, 1994; Roson et al, 1990a, 1990b, 1993). PTA is expressed in
various human tumours of different origins (reviewed in
Dominguez et al, 1997), supporting the idea that PTA expression is
required for tumour growth. Certainly, when PTA expression is
blocked the proliferation of myeloma cells is inhibited (Sburlati et
al, 1991). Non-transformed NIH 3T3 cells shows a similar behav-
iour (Rodriguez et al, 1998), indicating that PTA must play an
essential role in normal proliferation that is preserved in tumorous
cells. Moreover, when PTA is overexpressed the G1 phase of the
cell cycle is shortened (Rodriguez et al, 1998) as it also happens
with other factors that play a major role in cell proliferation. This
finding indicates that PTA must be a limiting factor necessary for
the progression of the cell cycle. On the other hand, the analysis of
the intracellular signalling pathways governing PTA expression
point to the fact that PTA expression is an event occurring down-
stream in several mitogenic pathways. PTA expression seems to be
under the direct control of MYC (Eilers et al, 1991); however,
other reports did not confirm this finding (Mol et al, 1995). Vareli
et al (1996) have found that the transcription factor E2F activates a
reporter gene under the PTA promoter, indicating that E2F could
directly control PTA expression. In mammary tumours arising in
c-myc, c-neu and v-ras transgenic mice we found that there is a
differential regulation of PTA with respect to other putative c-myc
target genes, indicating that regulation of PTA in these tumours is
complex and depends on more than a single activated oncogene
(Loidi et al, 1999).
PTA physiological function remains unknown. It is a nuclear
protein (Gomez and Segade, 1988; Roson et al, 1990a) that is
present throughout the cell cycle (Zalvide et al, 1992); it has been
shown that it binds histones in vitro (Papamarcaki and Tsolas,
1994; Diaz et al, 1996) and has been proposed to affect the chro-
matin state (Gomez-Marquez et al, 1998). Recently, we have
found that PTA modulates the activity of calcium/calmodulin-
dependent kinases (CaM-kinase) II and III in a cell cycle-depen-
dent manner (Vega et al, 1998). These enzymes play various roles
during the cell cycle. CaM-kinase III is necessary for the phospho-
rylation of EF-2 during mitosis (Ryazanov, 1987; Celis et al, 1990)
and CaM-kinase II affects the G1 progression as well as the transi-
tion from G2 to mitosis (Lu and Means, 1993).
We had previously shown in 71 patients with invasive ductal
carcinomas, that PTA levels as assayed by a radioimmunoassay
that detects thymosin a1, the NH2-terminal fragment of PTA, were
significantly greater in tumour samples than in normal breast
tissue. PTA levels were correlated with: (a) the number of positive
axillary lymph nodes, and (b) the percentage of tumour cells in the
S phase plus in the G2/M phase as assessed by flow cytometry. Of
special relevance was to find that PTA levels might be used to
identify patients at high risk for distant metastasis (Dominguez et
al, 1993). Recently, others independently confirmed these findings
(Tsitsilonis et al, 1998). In the present report, the role of tumour
PTA content as predictor was investigated with respect to both
disease-free survival and overall survival.
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Summary In a previous report we suggested that the estimation of prothymosin a (PTA) levels in primary breast tumours might be used to
identify breast cancer patients at high risk for distant metastasis (Dominguez F et al (1993) Eur J Cancer 29A: 893–897). Here the role of
tumour PTA levels as predictor was investigated with respect to both disease-free survival (DFS) and survival. Tumours were obtained from
a series of 210 consecutive female patients with ductal carcinoma who underwent surgery at the Hospital Xeral de Galicia (Santiago de
Compostela, Spain). Characteristics including PTA tumour levels, number of positive axillary nodes, patient’s age at surgery and tumour
histological grade were significantly associated with DFS and survival, as determined by univariate analysis. Patients with tumours with low
or moderate PTA levels demonstrated a statistically decreased rate of tumour recurrence and a statistically significant increased overall
survival in comparison with those whose tumours had high PTA levels. Patient’s relative risk of dying was 2.1 times greater for tumours with
high PTA levels than for those tumours with low or moderate PTA levels. In conclusion, these data support the hypothesis that tumour high
PTA levels is associated with a worse outcome. © 2000 Cancer Research Campaign
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Patients
High PTA levels in tumours have been suggested to be a predictor
of a poor prognosis (Dominguez et al, 1993). A prospective study
was designed to test this hypothesis. Tumours were obtained from
a series of 210 consecutive female patients with invasive ductal
carcinoma who underwent definitive surgery at the Hospital
General de Galicia (Santiago de Compostela, Spain) since 1989.
Patients with a second malignant neoplasm were excluded.
Specimen analysis
Each tissue block was sectioned for histological analysis as previ-
ously described (Dominguez et al, 1993). Nodal involvement was
histologically determined. Tumour grading was done according to
the Bloom and Richardson method as described by Freedman et al
(1979). Ploidy analysis was done by DNA flow cytometry.
Tumour samples were processed as previously described
(Dominguez et al, 1993).
PTA radioimmunoassay
PTA radioimmunoassay (RIA) was done as previously published
(Dominguez et al, 1993). Briefly, slices (about 200 mg) of tumour
tissues obtained during surgery were homogenized with a 
Polytron homogenizer in phosphate-buffered saline (PBS)-EDTA,
centrifuged at 14 000 g for 15 min and the supernatant analysed
for PTA and protein. The radiolabelled ligand was I125-Tyr0-
thymosin  a1 and synthetic thymosin a1 was employed to
standardize the assay. Tissue homogenates were prepared at room
temperature in order to convert tissue PTA to thymosin a1;
therefore, the results are expressed as thymosin a1 equivalents
(Dominguez et al, 1993).
Patient outcome end points
The role of tumour PTA levels as predictor was investigated with
respect to both disease-free survival (DFS) and survival; as
secondary end point, we also examined distant disease-free
survival (DDFS). DFS was defined as the time from surgery prior
to recurrent breast cancer or death from any cause. Survival was
defined as the time from surgery to death from any cause. DDFS
was defined as the time from surgery to tumour recurrence at
distant sites.
Statistical analysis
Logistic regression analysis, Kaplan–Meier survival analysis and
the Cox regression model were used. All data were analysed with
the use of the SPSS statistical package (SPSS Inc., Chicago, IL
USA).
RESULTS
Patient characteristics
Table 1 summarizes the clinical and biological data for all 210
patients enroled in this study. Patients were divided in three groups
according to tumour PTA content as follows: low level, PTA levels
ranging from 0 to 20 ng mg–1 of protein (34 patients); moderate
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Table 1 Patient and tumour characteristics
PTA levels
[No. (%)a]
Low Moderate High
No. of patients 210
Median follow-up, months
Median 36
Range 2–106
Tumour size, cm
≤2 15 (18) 49 (59) 19 (23)
>2 18 (14) 73 (58) 35 (28) 0.336b
No. of positive lymph nodes
None 19 (56) 44 (37) 17 (31)
1–3 11 (32) 37 (31) 13 (24)
4–9 2 (6) 22 (18) 14 (26)
³10 2 (6) 17 (14) 10 (18) 0.004b
Histological grade
Well differentiated 10 (32) 27 (23) 5 (10)
Moderately differentiated 15 (48) 54 (46) 15 (29)
Poorly differentiated 6 (19) 37 (31) 32 (61) 0.000b
DNA ploidy
Diploid 4 (44) 14 (28) 1 (4)
Aneuploid 5 (56) 36 (72) 21 (95) 0.008b
Age at surgery, (years)
≤ 39 1 (3) 9 (7) 7 (13)
40–49 4 (12) 26 (22) 11 (20)
³ 50 28 (85) 85 (71) 36 (67) 0.049b
aUnless otherwise specified, values in columns = number of subjects (%). bMantel–Haenszel test for linear association.level, PTA levels ranging from 20 to 100 ng mg–1 of protein (122
patients); and high level, PTA levels greater than 100 ng mg–1 of
protein (54 patients). A significant Pearson correlation was found
between PTA levels and number of positive lymph nodes (two-
sided P < 0.05), histological grade (two-sided P < 0.01), DNA
ploidy (two-sided P < 0.01) and patient’s age at surgery (P = 0.05).
By means of a logistic regression model relating PTA levels (high
vs low and moderate) with all co-variates, we found that the histo-
logical grade was significantly associated with PTA high levels (P
< 0.001). On the other hand, PTA low levels (low vs moderate and
high) were significantly associated with the absence of positive
nodes (P < 0.03) and with the histological grade (P < 0.03).
Analysis of outcomes
Table 2 shows estimates of the number of patients at risk and the
hazard rate for the first 5 years. Figure 1 shows Kaplan–Meier
plots for overall survival, DFS and DDFS for PTA levels. Patients
with low levels of PTA showed a superior behaviour to patients
with moderate or high PTA levels on the basis of each end point.
Characteristics including PTA tumour levels, number of positive
axillary nodes, patient’s age at surgery and tumour histological
grade were significantly associated with DFS and survival, as
determined by univariate analysis (Table 3). The same variables
plus tumour size were significantly associated with overall
survival (Table 3). The multivariate analysis of DFS and survival
is shown in Table 4. The effect of PTA levels, number of positive
lymph nodes and the histological grade is significant using the
multivariate model while tumour size and the age of the patient
loses the significance found in the univariate analysis.
As seen in Table 4 the risk of patients with tumours with high
PTA levels relative to tumours with low to moderate PTA levels is
high for both DFS and survival. In Figure 2, the data is stratified
according to other covariates of clinical relevance. The risk of
patients with tumours with high PTA levels relative to tumours
with low or moderate PTA levels is apparent among patients with
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Table 2 Number of patients exposed to risk and hazard rate
Survival DFS DDFS
No. hr ± s.e.m. No. hr ± s.e.m. No. hr ± s.e.m.
PTA Levels
Low Year
0 33.0 0.0000 ± 0.0000 33.0 0.0000 ± 0.0000 33.0 0.0000 ± 0.0000
1 32.0 0.0000 ± 0.000 32.0 0.0054 ± 0.0038 32.0 0.0026 ± 0.0026
2 26.5 0.0000 ± 0.000 25.0 0.0034 ± 0.0034 26.0 0.0033 ± 0.0033
3 18.5 0.0000 ± 0.000 17.0 0.0104 ± 0.0074 18.0 0.0048 ± 0.0048
4 11.5 0.0000 ± 0.000 8.5 0.0000 ± 0.0000 11.0 0.0000 ± 0.0000
5 4.5 0.0000 ± 0.000 3.0 0.0000 ± 0.0000 5.0 0.0185 ± 0.0184
Moderate 0 121.0 0.0014 ± 0.0010 121.0 0.0064 ± 0.0021 121.0 0.0028 ± 0.0014
1 114 0.0045 ± 0.0018 107.0 0.0162 ± 0.0037 112.0 0.0078 ± 0.0025
2 90 0.0048 ± 0.0021 72.0 0.0085 ± 0.0032 84.0 0.0030 ± 0.0017
3 55 0.0015 ± 0.0015 39.5 0.0066 ± 0.0038 53.0 0.0083 ± 0.0037
4 31 0.0055 ± 0.0039 18.5 0.0046 ± 0.0046 27.5 0.0063 ± 0.0044
5 15 0.0057 ± 0.0057 8.5 0.0000 ± 0.0000 12.5 0.0000 ± 0.0000
High 0 53.5 0.0048 ± 0028 54.0 0.0208 ± 0.0060 54.0 0.0170 ± 0.0053
1 48.5 0.0213 ± 0.0064 41.0 0.0156 ± 0.0059 43.0 0.0125 ± 0.0051
2 30.0 0.0119 ± 0.0059 27.5 0.0243 ± 0.0091 30.0 0.0220 ± 0.0082
3 16.0 0.0238 ± 0.0118 11.5 0.0250 ± 0.0143 13.0 0.0217 ± 0.0124
4 6.5 0.0500 ± 0.0275 4.0 0.1000 ± 0.0462 4.0 0.0556 ± 0.0370
5 2.0 0.1667 ± 0.0000
No., number of patients at risk; hr = hazard rate.
Table 3 Univariate analysis of variables associated with DFS and survival
DFS Survival
No. of
patientsa RRb 95% CI P c RRb 95% CI P c
PTA levels 209 1.61 1.28–2.03 0.0001 2.63 1.93–3.59 0.000
Tumour size (cm) 208 1.13 0.89–1.43 0.3045 1.48 1.05–2.09 0.022
Positive lymph nodes 208 1.40 1.08–1.81 0.0090 2.10 1.36–3.24 0.000
Histological grade 200 1.50 1.19–1.88 0.0024 1.96 1.44–2.67 0.000
Age at surgery (years) 206 0.76 0.60–0.96 0.0241 0.658 0.48–0.88 0.006
aNumber of patients indicates number with complete data. The numbers of patients’ tumours analysed are not identical for all
categories because of incomplete or unavailable data on some cases. bThe use of continuous variables provides lower P-
values, however, RR compares two categories for each variable. Therefore, for continuous variable, we selected specific
values to illustrate how to interpret the RR for the following variables: PTA levels (high vs low and moderate), size (> 2 cm vs
≤ 2 cm), lymph nodes (none vs ³ 1), histological grade (poorly differentiated vs well and moderately differentiated), age (>50
years vs ≤ 50 years). cP-values are from the Cox proportional hazards model with the use of the Walds’ test.Prothymosin a levels in breast cancer 587
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negative axillary lymph nodes. This is also true for other covari-
ates shown in Figure 2 but the number of patients in each stratum
is low; therefore, present data should be further validated. The
central hypothesis of this investigation was to see if patients with
tumours with high proliferating activity, as seen by estimating
tumour PTA levels, have a worse outcome. Bonferronis joint
multivariate analysis was used to test the effect of high PTA levels
on patient’s outcome using as primary end point survival, DFS and
DDFS and the following co-variates: tumour size (> 2 cm vs ≤2
cm), positive lymph nodes (none vs ³ 1), histological grade
(poorly differentiated vs well and moderately differentiated), and
age at surgery (> 50 years vs ≤ 50 years). The hypothesis was
significant for the three end points, survival (P = 0.000), DFS 
(P = 0.04149) and DDFS (P = 0.0001).
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Figure 1 Plot of estimated survival, DFS and DDFS function across PTA levels groups. Patients were divided in three groups according to tumour PTA content
as follows: low level, PTA levels ranging from 0 to 20 ng mg–1 of protein; moderate level, PTA levels ranging from 20 to 100 ng mg–1 of protein; and high level,
PTA levels greater than 100 ng mg–1 of protein. All patients with low PTA levels were alive during the period of observation588 C Magdalena et al
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DISCUSSION
The goal of the current study was to determine if tumours with
high PTA levels were associated with a worse outcome. We have
analysed the overall survival of patients with breast tumours that
underwent definitive surgery since the beginning of this study in
1989. PTA levels were assayed by a radioimmunoassay that
detects thymosin a1, the NH2-terminal fragment of PTA
(Dominguez et al, 1993). We present new evidences indicating that
estimation of PTA levels in the tumour is a potential prognostic
marker for primary breast cancer. A statistically significant associ-
ation between PTA levels and other relevant clinical factors as the
number of positive lymph nodes, the histological grade, DNA
ploidy and the age at surgery was observed. Patients with tumours
with low or moderate PTA levels demonstrated a statistically
significant decreased rate of tumour recurrence and a statistically
significant increased overall survival in comparison with those
patients whose tumours had high PTA levels. Multivariate Cox
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Figure 2 Risks of patients with high PTA levels tumours (l) relative to those of patients with tumours with low or moderate PTA levels. Risk of patients with
tumours with low or moderate PTA levels is considered to be 1 (dotted line). Relative risks of failure (RRs) and P-values shown on each plot are adjusted (Cox
model with the use of the Wald’s test) for patient’s lymph node status, age at the time of surgery, tumour size and the histological grade. Bars indicate 95%
confidence intervals. All P-values are two-sided. DFS = disease-free survival; DDFS = distant disease-free survival
Table 4 Multivariate Cox proportional analyses of variables associated with DSF and survival
DFS Survival
Variable RRa 95 % CI P b RRa 95 % CI P b
PTA levels 1.42 1.12–1.81 0.003 2.10 1.52–2.90 0.000
Tumour size, cm 1.04 0.82–1.32 0.721 1.25 0.87–1.78 0.219
Positive lymph nodes 1.31 1.01–1.70 0.038 1.78 1.15–2.75 0.030
Histological grade 1.34 1.06–1.69 0.014 1.44 1.03–2.01 0.007
Age at surgery, (years) 0.84 0.67–1.07 0.174 0.84 0.61–1.15 0.287
aThe use of continuous variables provides lower P-values, however, RR compares two categories for each
variable. Therefore, we selected specific values to illustrate how to interpret the RR for the following variables:
PTA levels (high versus low and moderate), size (> 2 cm vs ≤ 2 cm), lymph nodes (none vs ³ 1), histological
grade (poorly differentiated vs well and moderately differentiated), age (>50 years vs ≤ 50 years). bP-values
are from the Cox proportional hazards model with the use of the Walds’ test.proportional analyses showed that those patients with high PTA
levels have 2.1 times the risk of dying than patients with low or
moderate PTA levels. Moreover, patients with high PTA levels had
a greater risk (1.42 times) of regional or distant tumour recurrence
than patients with low or moderate PTA levels. However, these
numbers must be taken with caution since, as always, the model
will fit the sample from which it is estimated better than it will fit
the population from which the sample is selected. Bonferronis
joint multivariate analysis was used to test the effect of high PTA
levels on patient’s outcome using as primary end point survival,
DFS and DDFS. PTA levels had significant effect on the three end
points. The fact that the three end points were significantly
affected provides a stronger support to the hypothesis that patients
with tumours with high PTA levels have a worse outcome. These
findings are not surprising since cell proliferation indices have
been shown to be prognosis-related (Freedman et al, 1979;
Sigurdsson et al, 1990). By means of immunohistochemical tech-
niques we found that PTA and the proliferating cell nuclear
antigen (PCNA) had a similar pattern of expression both in normal
tissues (Roson et al, 1993) and hepatocellular carcinomas (Fraga et
al, 1993). PTA is expressed in the late G1, S, G2 and M phases of
the cell cycle (Zalvide et al, 1992). Interestingly, the fraction of
cells in S and G2 phases is more closely associated with the clin-
ical outcome than the S phase fraction alone (Witzig et al, 1994).
Recently, Rudolph et al, using the proliferation marker Ki-S2
concluded that the prognosis is best indicated by the percentage of
cells in S through M phases of the cell cycle (Rudolph et al, 1999).
In agreement with this we found in breast tumours that PTA
expression was correlated with the percentage of cells in S and
G2/M phases fraction but not with the S phase alone (Dominguez
et al, 1993). Here we presented the estimation of tumour prolifer-
ation rate as assessed using a RIA for PTA. PTA RIA provides an
objective measure of tumour proliferation activity.
A major trend in the biologic research in breast cancer is
focused in factors that predict benefit from therapy. At present, it is
not possible to identify those patients who are cured without adju-
vant chemotherapy or those patients who will relapse in spite of
adjuvant chemotherapy, with resistant disease (Powles, 1997).
Tumour PTA content was investigated as predictor with respect to
DFS, DDFS and overall survival. Patients received surgical, radia-
tion and other adjuvant therapies following an established pattern,
irrespectively of tumour PTA content. Patients with tumours with
high PTA levels had a worst outcome irrespective of the adjuvant
therapy received. On the other hand, tumours with low levels of
PTA had a good prognosis. Further studies with a larger series of
patients are now needed to establish the role of tumour PTA as a
predictor of the therapeutic response. However, it is interesting to
point out that PTA antisense oligonucleotides that blocks PTA
expression promoted apoptosis in HL60 cells (Rodriguez et al,
1999). If this finding is confirmed it is tempting to speculate that
high PTA levels could have a protective effect against apoptosis
induced by chemotherapeutic agents.
In summary, this paper reaffirms two major points in breast
cancer research: first, the importance that tumour’s proliferation
rates have in patient’s outcome and, second, the benefit of using
quantitative assays to estimate proliferation rates. We propose that
PTA content could be used as a predictor of the potential malig-
nancy of breast tumours that might help to identify patients at high
risk of dying. Our study represents a preliminary attempt to corre-
late tumour PTA levels and overall mortality in breast cancers.
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